Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis

Blin, Patrick; Philippe, François; Bouée, S.; Laurendeau, C.; Torreton, E.; Gourmelin, J.; Leproust, S.; Lévy-Bachelot, L.; Steg, Philippe Gabriel

doi:10.1016/j.ijcard.2016.06.102

Cited by 22 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well-established that the risk of MACE is elevated in patients with CAD and a previous CV event. Two studies demonstrated that the risk of MACE remains high for up to 4.5 years after an MI (Figures 2(a) and 2(b)) [3,4].…”

Section: Humanistic Burdenmentioning

confidence: 99%

“…Patients with depression had a higher risk of death and admission for MI compared with those with CAD without depression [40]. Like CV Figure 2: The persistent risk of MACE (a) up to 3 years following an index MI (adapted from Blin et al, 2016) [3] and (b) up to 4.5 years following an index MI stratified by age (<72 years old versus ≥72 years old) and risk category (low versus high a ) (adapted from Jernberg et al, 2015) [4]. a High-risk patients were predefined as those with ≥1 of the following risk factors prior to index; MI: diabetes mellitus, at least one MI prior to index MI event, CABG (proxy for multi-vessel CAD), PAD, stroke, heart failure, or diagnosis of chronic renal dysfunction.…”

Section: Humanistic Burdenmentioning

confidence: 99%

See 1 more Smart Citation

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review

Bauersachs

Zeymer

Brière

et al. 2019

Cardiovascular Therapeutics

270

153

View full text Add to dashboard Cite

Background. Atherothrombotic disease, including coronary artery disease (CAD) and peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial infarction, stroke, limb ischemia, heart failure, and CV death. Aim. Evaluate the humanistic and economic burden of CAD and PAD and identify unmet needs through a comprehensive literature review. Methods. Relevant search terms were applied across online publication databases. Studies published between January 2010 and August 2017 meeting the inclusion/exclusion criteria were selected; guidelines were also included. Two rounds of screening were applied to select studies of relevance. Results. Worldwide data showed approximately 5–8% prevalence of CAD and 10–20% prevalence of PAD, dependent on the study design, average age, gender, and geographical location. Data from the REACH registry indicated that 18–35% of patients with CAD and 46–68% of patients with PAD had disease in one or more vascular beds. Use of medication to control modifiable CV risk factors was variable by country (lower in France than in Canada); statins and aspirin were the most widely used therapies in patients with chronic disease. Survival rates have improved with medical advancements, but there is an additional need to improve the humanistic burden of disease (i.e., associated disability and quality of life). The economic burden of atherothrombotic disease is high and expected to increase with increased survival and the aging population. Conclusion. CAD and PAD represent a substantial humanistic and economic burden worldwide, highlighting a need for new interventions to reduce the incidence of atherothrombotic disease.

show abstract

Section: Humanistic Burdenmentioning

confidence: 99%

Section: Humanistic Burdenmentioning

confidence: 99%

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review

Bauersachs

Zeymer

Brière

et al. 2019

Cardiovascular Therapeutics

270

153

View full text Add to dashboard Cite

show abstract

“…Death rates based on French life tables, were applied to all modelled states. A number of health states included an additional specific event-related mortality risk, as identified from a literature review on RWE studies in France [16][17][18][19], assuming no event-related mortality followed hospital discharge.…”

Section: Clinical Data Implementationmentioning

confidence: 99%

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

et al. 2020

View full text Add to dashboard Cite

ObjectiveThe objective was to assess the real-world cost-effectiveness of rivaroxaban, versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation (AF) from a French national health insurance perspective.Funding: LF, CC and PL received honorarium from Bayer AG for critical input into study design and results analysis. Bayer Plc. provided support in the form of salaries for author KB; Bayer AG provided support in the form of salaries for author JBB. Bayer AG sponsored the study, and Bayer AG as well as Bayer Plc had a role in the study design, ConclusionsAlthough there is no official willingness-to-pay threshold in France, these results suggest that rivaroxaban is likely to be cost-effective compared to VKA in French patients with AF from a national insurance perspective. Introduction/BackgroundAtrial fibrillation (AF) is a cardiac arrhythmia with structural and/or electrophysiological abnormalities that induce remodelling in the atria; it is the most common cardiac arrhythmia [1][2][3]. Worldwide, an estimated 3% of adults aged 20 years or older suffer from AF, approximately 20.9 million men and 12.6 million women [2]. Due to the aging of the population, the worldwide prevalence is predicted to at least double in many countries during the next several decades [4,5].AF is associated with substantial morbidity and mortality [2]. Compared to otherwise healthy individuals, men and women with AF are at a 1.5-fold and 2-fold increased risk for allcause mortality, respectively [2], and the risk for strokes increased by 2-to-7-fold [4]. Strokes are associated with significant financial burden [6]; in 2015, the total costs of stroke care in the European Union (EU) was estimated to be €45 billion euros [7]. It is expected that between 2015 and 2035, there will be a 34% increase in total number of stroke events in the European Union [7].Oral anticoagulants including vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban, have been established as a cornerstone of management in patients with AF and to reduce stroke incidence and mortality [2] in randomized clinical trials (RCTs) [2].Many uncertainties remain regarding the relevance of the results of RCTs in a real-world setting. Real-world evidence (RWE) may provide additional information to decision-makers [8]. Indeed, RWE sample size is not limited as it is the case of RCTs. RCTs have to respect inclusion/exclusion criteria regarding population selection. Also, RWE can offer long-term outcomes while the timeframe of RCT is usually shorter with only a few outcomes [9].A meta-analysis comparing NOACs with VKAs and reporting effectiveness, safety, and persistence using RWE has recently been published [10]. It confirmed the findings of rivaroxaban pivotal RCT [11] and concluded that rivaroxaban is a suitable alternative to VKAs in routine clinical practice. Health Technology Assessment (HTA) agencies are frequently requesting manufacturers to prove the benefits of their hea...

show abstract

“…Patients who died during this 90-day period were not included, early recurrence or death in the weeks following an initial ACS events being considered as depending essentially on the seriousness of the first event and only marginally on the effectiveness of the secondary prevention. 39 Drug exposure Drugs of interest were the four EBCMs recommended in secondary prevention of ACS: ACEIs or ARBs, APAs (aspirin and/or P2Y 12 inhibitor), beta-blockers, and statins. For each EBCM, the number of days of supply for each dispensing was defined as the number of tablets dispensed (assuming a treatment schedule of one tablet per day), to which a grace period equal to 10% of the number of tablets dispensed was added.…”

Section: Study Populationmentioning

confidence: 99%

Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real‐Life Setting

Bezin

Klungel

Lassalle

et al. 2017

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Long-term effectiveness of evidence-based cardiovascular medications (EBCMs) indicated after acute coronary syndrome (ACS) needs to be assessed considering the combination effects for these drugs recommended in association. Using a nationwide database, we conducted a cohort study to evaluate the effectiveness of all possible incomplete EBCMs-based combinations as compared to that associating the four recommended EBCMs over up to 5 years of follow-up. Among the 31,668 patients included, 22.9% had ACS recurrence or died during follow-up. The risks associated with the use of 3-EBCM based combinations were 1.46 (95% confidence interval: 1.33-1.60) for the combinations without statins, 1.30 (1.17-1.43) for the combinations without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 1.11 (0.98-1.25) for the combinations without antiplatelet agents, and 0.99 (0.89-1.10) for the combination without beta-blockers. These findings question the interest of maintaining long-term treatment with beta-blockers in addition to the other EBCMs for post-ACS secondary prevention.

show abstract

Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis

Cited by 22 publications

References 20 publications

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real‐Life Setting

Contact Info

Product

Resources

About